How profitable is Cel-Sci Corporation (CVM)?

In FY 2025 (10-K), CVM converted $69.5M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / CVM / financials

EVAX (46) ESLA (38) BSEM (35) MGX (23) ⌘ Pro Terminal →

Cel-Sci Corporation (CVM) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.31 -5.07% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.30

Cel-Sci Corporation (CVM) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $24.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CVM Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CVM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Cel-Sci Corporation (NYSE: CVM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.31 (-5.07% 1D, market cap $24.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CVM compare to EVAX and ESLA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CVM carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EVAX (Evaxion A/S) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $26.4M) and ESLA (Estrella Immunopharma Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $27.8M). Among the 5-stock peer group, CVM leads on earnings multiple (N/A) while BSEM leads on capital efficiency (-5.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CVM?

▼

Per CVM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0000725363), Cel-Sci Corporation generated $69.5M in revenue (-5.9% YoY), -$25.4M in net income, and -$17.2M in free cash flow against $22.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.30 (-1.10%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CVM)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (35/100 Composite)

🔍 WHY CVM SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (26% of score)

FRED Regime × Technicals: 6% of 52W Range • RSI-14 at 38.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.75-11.4% Next Q

Q2 (-2Q)

Grade D$1.55+1.3% Next Q

Q3 (-1Q)

Grade E$1.57-16.6% Next Q

Current

Grade D-$1.31-8.5% Hist 90D α

Trajectory: D (43) → D- (35)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CVM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CVM currently carries a cautious 35/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.70) and Max Pain ($1.38) forces dealer call-delta covering toward $8.19.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CVM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CVM Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 35%NO 65%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How CVM Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $88.1M

FY24

Rev $73.8M

FY25

Rev $69.5M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$69.5M	52%	-35.7%	-$25.4M	-$17.2M	-45%
FY 2024	$73.8M	52%	-35.7%	-$26.9M	-$18.9M	-45%
FY 2023	$88.1M	52%	-35.7%	-$32.4M	-$22.8M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CVM)

✓Walkthrough of CVM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CVM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -22.49%▼ SUPPORT BREAKDOWN

2026-11-03O $1.50H $1.50L $1.31C $1.31VOL 190.0K

RES: $3.03SUP: $1.70SMA50: $1.70SMA200: $2.48

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CVM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CVM Butterfly Map → + Track CVM →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -5.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CVM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CVM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CVM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CVM)

Health Care Rank #607 of 1015 ⚔️ EVAX vs CVM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CVM vs. EVAX, ESLA, BSEM, MGX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Cel-Sci Corporation (CVM) ranks #607 by composite RQD confidence (35/100, grade D-) and #819 by equity capitalization ($24.3M). Within this direct 5-issuer industry benchmark cohort, CVM leads on earnings valuation at N/A trailing P/E, while BSEM leads on capital efficiency and profitability with -5.7% ROIC and 93.6% gross margin. EVAX currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with CVM at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CVM ACTIVE Cel-Sci Corporation	D-	35/100	—	—	-35.0%	-5.07%	$24.3M	Benchmark Subject
EVAX Evaxion A/S	D	46/100	—	—	—	-0.34%	$26.4M	/evax-vs-cvm →
ESLA Estrella Immunopharma Inc.	D-	38/100	—	—	-35.0%	-33.32%	$27.8M	/esla-vs-cvm →
BSEM BioStem Technologies Inc.	D-	35/100	—	93.6%	-5.7%	+3.57%	$20.9M	/bsem-vs-cvm →
MGX Metagenomi Therapeutics Inc.	E	23/100	—	—	-35.0%	-3.24%	$29.5M	/mgx-vs-cvm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0000725363 ↗

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Cel-Sci Corporation (CVM) reported GAAP revenue of $69.5M (-5.9% vs. FY2024 revenue of $73.8M , and -21.2% cumulative change since FY2023) , GAAP net income of -$25.4M, operating cash flow of -$17.1M, and free cash flow of -$17.2M (+9.2% YoY). On the balance sheet, CVM closed FY2025 with $22.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$69.5M	-$25.4M	-$17.1M	-$17.2M	$22.9M	—
FY2024 (FY)	2024-09-30	$73.8M	-$26.9M	-$18.8M	-$18.9M	$25.7M	—
FY2023 (FY)	2023-09-30	$88.1M	-$32.4M	-$22.8M	-$22.8M	—	—

3. CVM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CVM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CVM compare to EVAX and ESLA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CVM?

Where is CVM trading relative to its 50-day, 200-day, and 52-week technical levels?

CVM last traded at $1.31 (-5.07% on volume of 91,943 shares), positioning the stock -22.94% below its 50-day simple moving average ($1.70) and -47.18% below its 200-day simple moving average ($2.48). Across its 52-week range of $0.89 to $7.80, CVM sits at the 6.1% percentile with a 14-day RSI of 38.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.15 to $1.47).

Direct Sub-Reports: CVM RQD Cockpit CVM 12M Forecast CVM Earnings & Move CVM Dividends & DRIP CVM Insiders & 13F CVM Whale Options CVM Profit Sankey CVM News & Why

ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ SEC XBRL & RQD VERIFIED

CVM — Cel-Sci Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-09-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Cel-Sci Corporation (CVM) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.31 (-5.07% 1D, market capitalization $24.3M).

Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Cel-Sci Corporation (CVM) is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. It carries a market capitalization of $0.0B on the profile line, which conflicts with the $26.4M figure in market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-09-30), Cel-Sci Corporation (CVM) reported $69.5M in annual revenue (up from $73.8M in FY2024, -5.9% YoY) and -$25.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($88.1M revenue, -$32.4M net income) through FY2025, CVM scaled operating cash flow to -$17.1M and free cash flow to -$17.2M, backed by $22.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.89 – $7.80 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only cross-asset linkage is the liquidity-beta relationship in the proprietary signal (3.86x Net Liquidity elasticity), which indicates sensitivity to Fed balance-sheet and liquidity conditions rather than to a named supplier or customer. Second-order bottlenecks cannot be identified from the source data.

Key Question #1: Can CVM sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $69.5M and free cash flow of -$17.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is CVM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CVM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cel-Sci Corporation (CVM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CVM Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

CEL-SCI Corporation (CVM) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Cel-Sci Corporation (CVM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

CEL-SCI reports survival data from Multikine cancer study

Investing.com report covering Cel-Sci Corporation (CVM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.siam.in/ • 1d ago

Cel-Sci Corporation (CVM) Jumps 11.98% to $2.71 as Buyers Push Toward Resistance - ETF AUM Growth

https://www.siam.in/ report covering Cel-Sci Corporation (CVM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Business Wire • 1d ago

CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival

Business Wire report covering Cel-Sci Corporation (CVM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

CEL-SCI reports 73.4% five-year survival in Multikine Phase 3 patient analysis

Yahoo Finance report covering Cel-Sci Corporation (CVM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE RTTNews • 1d ago

Morning Market Movers: BRAI, AIOK, MFIC, CLRO See Big Swings

RTTNews report covering Cel-Sci Corporation (CVM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 8d ago

CEL-SCI Presents New Pre-Surgical Data From Its Phase 3 Trial Of Multikine At World Congress; Locally Advanced Primary Tumor With No Detectable Lymph Node Involved; Tumor Proportion Score Less Than 10%

CEL-SCI Corporation (NYSE:CVM) today announced positive new pre-surgical tumor response and safety analyses from its completed Phase 3 study of Multikine® (Leukocyte Interleukin, Injection)*. The findings were presented

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CVM Bull vs. Bear Conversation Board — What's Your Call at $1.31?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CVM 🐻 33% BEARISH CONVICTION

CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $1.71 (+23.9%)

📌 Pinned Debate

Multikine Phase 3 analyses reporting 73% five-year survival in a biomarker-identified subgroup, alongside a 96/100 macro tailwind score

Here is why I am bullish on CVM here at $1.38: Multikine Phase 3 analyses reporting 73% five-year survival in a biomarker-identified subgroup, alongside a 96/100 macro tailwind score from the liquidity signal.. Compare CVM's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Biological Products (No Diagnostic Substances). As long as cash conversion holds up, dips toward $1.31 are getting bought.

EarningsSniper 🐂 BULL

@RiskArb_Desk Shorting a 3/20 institutional whale-flow stock at $1.38 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $1.03 (-25.4%)

Spot @ $1.38

Negative ROIC of -35%, a 0% FCF yield, and an RQD score of 36 with weak institutional and insider flow pillars.

Sitting on the sidelines or leaning short CVM above $1.38. Negative ROIC of -35%, a 0% FCF yield, and an RQD score of 36 with weak institutional and insider flow pillars.. Until Fundamental Cash Engine (8/20) and FCF yield (0.0%) inflect higher, upside is capped near $7.80.